Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Cell Models for Research

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a rare inherited cardiac disorder characterized by stress-induced polymorphic ventricular arrhythmias, leading to syncope and sudden cardiac death (SCD) in individuals with structurally normal hearts. The exact global prevalence is unknown, but estimates suggest 1 in 10,000 to 1 in 50,000 individuals, based on data from the World Health Organization (WHO) and Orphanet. CPVT accounts for approximately 10-15% of unexplained sudden cardiac deaths in young people and children, with a mean age of onset around 7-12 years. The 5-year survival rate is difficult to define due to the episodic nature of arrhythmias, but without treatment, the mortality rate can reach 30-50% by age 30, as reported by the National Cancer Institute (NCI) and cardiology registries. Key risk factors include a family history of CPVT or SCD, pathogenic variants in genes encoding cardiac calcium-handling proteins, and physical or emotional stress. The disease is a significant model for studying cardiac electrophysiology, calcium signaling, and arrhythmogenesis.

CPVT is an ideal model for mechanistic studies because it is a monogenic disorder with high penetrance, allowing for clear genotype-phenotype correlations. The primary genetic causes are mutations in the RYR2 gene (encoding the cardiac ryanodine receptor) and CASQ2 (encoding calsequestrin 2), which are critical for calcium-induced calcium release in cardiomyocytes. Public datasets, such as ClinVar and the Human Gene Mutation Database (HGMD), provide curated lists of pathogenic variants. Open questions include the precise molecular mechanisms of arrhythmia initiation, the role of modifier genes, and the development of targeted therapies. Gene-edited cell models, such as CRISPR knockouts and knock-ins, are invaluable for dissecting these pathways and testing potential drugs.

While CPVT is not a cancer, the term 'carcinogenic' is not applicable. Instead, the core molecular pathways are arrhythmogenic. The primary pathway involves abnormal calcium handling in cardiac myocytes:

• • Under stress (beta-adrenergic stimulation), the sympathetic nervous system activates protein kinase A (PKA), which phosphorylates the ryanodine receptor (RYR2) and phospholamban.
• • In normal conditions, this enhances calcium release from the sarcoplasmic reticulum (SR) and reuptake via SERCA2a, maintaining calcium homeostasis.
• • In CPVT, mutations in RYR2 or CASQ2 cause 'leaky' SR calcium release during diastole, leading to delayed afterdepolarizations (DADs) and triggered arrhythmias.
• • The resulting calcium overload activates the sodium-calcium exchanger (NCX), generating transient inward currents that depolarize the cell membrane.
• • This can trigger polymorphic ventricular tachycardia, often bidirectional, which can degenerate into ventricular fibrillation and sudden death.

Data from ClinVar, UniProt, and COSMIC (for somatic variants, though CPVT is germline) indicate the following high-frequency genetic alterations:

Note: Frequencies are approximate and based on ClinVar and literature. COSMIC primarily catalogs somatic mutations in cancer, but RYR2 mutations are rarely somatic; the data here is from germline databases.

The key deregulated signaling networks in CPVT include:

• • Beta-adrenergic signaling: Activation of PKA and CaMKII, which phosphorylate RYR2, increasing its open probability. In CPVT, this is exaggerated.
• • Calcium handling network: Involves RYR2, CASQ2, triadin, junctin, SERCA2a, and NCX. Mutations disrupt the balance between SR calcium release and reuptake.
• • Calmodulin (CaM) signaling: CaM binds to RYR2 and regulates its activity. CALM1 mutations impair this regulation.
• • Reactive oxygen species (ROS) signaling: Stress-induced ROS can further sensitize RYR2, exacerbating calcium leak.

Key nodes for therapeutic targeting include RYR2, CaMKII, and NCX.

Common cell lines used in CPVT research include:

Organoids, such as cardiac microtissues or engineered heart tissues (EHTs), offer a more physiologically relevant 3D environment, allowing for the study of cell-cell interactions and drug responses. They are particularly useful for testing arrhythmogenic potential.

Animal models for CPVT include:

• • Genetically engineered mouse models (GEMMs): Knock-in mice carrying RYR2 mutations (e.g., RYR2-R4496C, RYR2-P2328S) or CASQ2 knockout mice. These recapitulate the arrhythmia phenotype under stress.
• • Induced models: Pharmacological induction using caffeine or isoproterenol to trigger arrhythmias in wild-type mice, but these are less specific.
• • Patient-derived xenografts (PDX) are not applicable to CPVT as it is not a cancer; instead, humanized mouse models with patient-specific mutations are used.
• • Zebrafish models: Transgenic zebrafish expressing mutant RYR2, used for high-throughput drug screening.

Each model has advantages and limitations in terms of translational relevance, cost, and throughput.

CRISPR-based gene editing has revolutionized CPVT research by enabling the creation of isogenic cell lines with precise mutations. These models include:

• • RYR2 knockout cell lines (e.g., in HEK293 or iPSC-CMs) to study loss-of-function effects.
• • RYR2 knock-in cell lines with specific pathogenic variants (e.g., RYR2-R4496C, RYR2-P2328S) to model gain-of-function.
• • CASQ2 knockout or knock-in lines to study calcium buffering defects.
• • Reporter lines with fluorescent calcium indicators (e.g., GCaMP) to monitor calcium dynamics in real time.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing consistent, reproducible systems. These models are essential for drug screening, functional validation, and mechanistic studies. They are available from commercial sources, but specific company names are not mentioned here.

Gene-edited cells are used to validate the functional impact of CPVT-associated variants. For example:

• • CRISPR knockout of RYR2 in iPSC-CMs leads to reduced calcium release, confirming its role in excitation-contraction coupling.
• • Knock-in of RYR2-R4496C in HEK293 cells shows increased SR calcium leak, as measured by Fura-2 or Fluo-4 imaging.
• • CASQ2 knockout in iPSC-CMs results in reduced calcium buffering and arrhythmic beats, as observed in microelectrode array (MEA) recordings.

These models allow for the study of gene function in a controlled genetic background, eliminating confounding factors.

Isogenic pairs (wild-type vs. mutant) are ideal for high-throughput drug screening. For example:

• • Screening for compounds that reduce SR calcium leak in RYR2-mutant cells, using calcium imaging as a readout.
• • Testing the efficacy of known antiarrhythmic drugs (e.g., flecainide, beta-blockers) on mutant vs. wild-type cells.
• • Modeling drug resistance by exposing cells to increasing concentrations of a drug and selecting for resistant clones, which can then be sequenced to identify secondary mutations.

Gene-edited cells provide a reproducible platform for dose-response studies and toxicity assessment.

CRISPR-based synthetic lethality screens can identify novel therapeutic targets. For example:

• • In RYR2-mutant cells, knocking out genes involved in calcium handling (e.g., CaMKII, NCX) may reveal synthetic lethal interactions that could be exploited therapeutically.
• • CRISPR activation (CRISPRa) screens can identify genes that suppress arrhythmic phenotypes, providing potential drug targets.
• • Transcriptomic and proteomic analyses of gene-edited cells can identify biomarkers of disease severity or drug response.

These approaches accelerate the discovery of precision medicine strategies.